Submitted by Dr. Fabian Kiessling with his team at the Institute of Experimental Molecular Imaging (ExMI*), University Hospital Aachen and Helmholtz Institute for Biomedical Engineering at RWTH Aachen University.
The merging of drug therapy and diagnostics to advance personalized medicine is one definition of theranostics. Research in advanced theranostics elevates this concept by merging nanotechnology to benefit drug discovery.
Such research is the direction for Dr. Fabian Kiessling and his team at the Institute for Experimental Molecular Imaging (ExMI*), University Hospital Aachen and Helmholtz Institute for Biomedical Engineering at RWTH Aachen University.
In fact, a recent report by Lammers et al addresses one of the major challenges of biomedical and (nano-) pharmaceutical research. Lammers published on the efficient and safe opening of the blood brain barrier using USPIO-loaded polymeric microbubbles in combination with high frequency ultrasound imaging on the Vevo 2100 and showed the delivery of a fluorescent macromolecular model drug into the brain tissue.
*ExMI is part of a consortium that is recommended as a Euro-BioImaging node for preclinical multimodal molecular imaging.
PRE-DELIVERY:
POST-DELIVERY: